The Luvmeebody Wellnessclub/Blogs/Articles

A New Chapter in Weight Management

GLP-1 receptor agonists, a class of medications including semaglutide and tirzepatide, have fundamentally changed the conversation around weight management. These drugs, originally developed for type 2 diabetes, have shown significant efficacy for weight loss, bringing hope and new options to many [4].

They work by mimicking a natural gut hormone, glucagon-like peptide-1, which helps regulate appetite and food intake by signaling satiety to the brain [4]. The results seen in clinical trials have been substantial. However, a critical question is now coming into focus as more people use these therapies: what happens when the medication is stopped?

New evidence is providing a clear, if sobering, answer, prompting an important shift in how we think about the role of these medications in a long-term wellness strategy.

What the Research Shows

Two major clinical trials published in the Journal of the American Medical Association (JAMA) have shed light on the effects of discontinuing GLP-1 therapy. The findings suggest that the body’s weight regulation systems are powerfully influenced by these medications, and their absence leads to a predictable reversal.

A 2022 study, an extension of the landmark STEP 1 trial, followed participants for one year after they stopped taking a weekly 2.4 mg dose of semaglutide. During the trial, participants had lost an average of nearly 17.3% of their body weight. Within a year of discontinuing the drug, they had regained approximately two-thirds of that lost weight [1]. The study also noted that the cardiometabolic improvements seen during treatment, such as better blood pressure and cholesterol levels, largely reverted to pre-treatment levels [1].

More recently, a 2023 study on tirzepatide, a dual GIP and GLP-1 agonist, produced similar findings. In the SURMOUNT-4 randomized clinical trial, participants who continued taking tirzepatide after an initial 36-week period maintained their weight loss and saw further reduction. In contrast, those who were switched to a placebo after 36 weeks regained a significant portion of their lost weight [2]. Specifically, by the end of the 88-week trial, the placebo group had regained about 14% of their body weight, while the group continuing treatment lost an additional 5.5% [2].

These results underscore a key concept in weight science: the body’s tendency to defend its highest sustained weight, a phenomenon involving metabolic adaptation [3]. When weight is lost, the body often responds by increasing hunger signals and reducing energy expenditure to encourage a return to its previous state. The research suggests that GLP-1 medications effectively counteract these signals, but only while they are being actively taken [1, 2].

What This Means for Everyday Wellness

The primary takeaway from this research is that obesity is increasingly understood and treated as a chronic, long-term condition, much like high blood pressure or diabetes. The evidence shows that GLP-1 agonists are not a short-term ‘cure’ but rather a long-term management tool [1, 2]. Discontinuing them without a structured plan often leads to weight regain.

This reframes the conversation around their use. A decision to start these medications, made in partnership with a healthcare provider, should also involve a discussion about the intended duration of treatment and a plan for what happens if the medication is stopped. For many, this may mean indefinite use to maintain the health benefits.

Regardless of medication, foundational wellness practices remain the cornerstone of sustainable health. The CDC emphasizes that long-term weight management is most successful when it includes a balanced eating plan, regular physical activity, adequate sleep, and stress management [5]. These habits are not replaced by medication but are critical complements to it, helping to support metabolic health and overall well-being for the long haul.

A Gentle Reminder

Your wellness journey is unique and requires a sustainable, long-term perspective. Always partner with your qualified healthcare provider to create a comprehensive and individualized plan that supports your health goals safely and effectively.

Sources and Resources

1. [1] JAMA. Weight Regain and Cardiometabolic Changes After Withdrawal of Semaglutide: The STEP 1 Trial Extension (2022-08-23). https://jamanetwork.com/journals/jama/fullarticle/2795627
2. [2] JAMA. Weight Regain and Cardiometabolic Effects After Discontinuing Tirzepatide: The SURMOUNT-4 Randomized Clinical Trial (2023-12-11). https://jamanetwork.com/journals/jama/fullarticle/2812936
3. [3] Harvard T.H. Chan School of Public Health. Metabolic slowing and weight regain: The role of carbohydrate-insulin model (2022). https://www.health.harvard.edu/blog/metabolic-slowing-and-weight-regain-the-role-of-carbohydrate-insulin-model-202209262822
4. [4] Mayo Clinic. Should you take a GLP-1 drug for weight loss? (2024-03-22). https://www.mayoclinic.org/healthy-lifestyle/weight-loss/expert-answers/glp-1-drugs/faq-20546110
5. [5] CDC. Losing Weight (2022-09-22). https://www.cdc.gov/healthyweight/losing_weight/index.html

---

Educational disclaimer: This article is for general wellness education only. It is not medical advice and does not diagnose, treat, cure, or prevent any condition. It is not a substitute for consultation with a qualified healthcare professional. Always speak with your clinician before starting or changing any medication, supplement, or wellness routine, especially if you are pregnant, nursing, taking medication, or managing a health condition.

---

Explore more guided wellness at
The Luvmee Body Wellness Club.

---